By Admore Mbonda in Kariba
The Stop TB Partnership’s Global Drug Facility (GDF) has announced a dramatic 54% reduction in the price of bedaquiline, a key treatment for drug-resistant tuberculosis (DR-TB), bringing the cost of a full treatment course down to just $90 from $194.
This substantial price drop is a crucial development for Zimbabwe, where access to essential TB medications is a pressing need.
In addition to the bedaquiline price cut, the GDF has also reduced the cost of other DR-TB drugs by up to 13%, lowering the price of the six-month BPaLM regimen to an all-time low of $364.
These price reductions are projected to save $7.1 million over two years, enabling the procurement of 79,000 more treatments—vital, given that only 176,000 people are treated for DR-TB globally each year.
“This price reduction makes bedaquiline more accessible and affordable for many patients,” said Donald Rungoyi, Chairman of Stop TB Partnership Zimbabwe.
He noted that the reduced cost could improve treatment outcomes and curb the spread of drug-resistant TB strains.
Community leaders are also optimistic, with calls for the government to take a stronger role in drug procurement to improve access to treatment.
Dr Donald Tobaiwa from the Jointed Hands Welfare Organisation stressed that increased domestic funding could help mitigate the impact of declining global support.
However, experts are calling for a more comprehensive approach. Olive Mutabeni from Life Empowerment Support Organisation highlighted the importance of providing nutritional support to patients, emphasizing that medication effectiveness is often enhanced by proper nutrition.
As Zimbabwe works to strengthen its national TB control efforts, this price reduction is a significant step forward in the global fight against TB, contributing to the United Nations’ goal of ending the epidemic by 2030.
About Author
